Antidepressant Carcinogen Recall
Breckenridge Pharmaceutical Recalls Antidepressant Duloxetine Over Potential Cancer-Causing Impurity
Breckenridge Pharmaceutical, Inc. is voluntarily recalling nearly 370,000 bottles of Duloxetine delayed-release capsules after tests found levels of a probable cancer-causing substance above the FDA's accepted limit. KSN reported the affected drug is used to treat depression, anxiety, and fibromyalgia — conditions that affect millions of Americans.
The contaminant is called N-nitroso-duloxetine. It belongs to a class of chemicals known as nitrosamines, which are classified as probable human carcinogens. The FDA says the risk from short-term exposure is low, but the sheer scale of the recall — spanning multiple dosages and hundreds of thousands of bottles — has raised alarm among patients and healthcare providers alike.
What the Recall Covers and Who Is Affected
The recalled bottles include 20mg, 30mg, and 60mg capsules in various bottle sizes — from 90-count to 1,000-count containers. The initial Breckenridge recall in October 2024 covered 7,107 bottles, according to CBS News. A second, larger recall by Rising Pharmaceuticals in November 2024 added more than 233,000 bottles across three dosages.
The bottles were distributed across the United States. Duloxetine is the generic version of Cymbalta. It is one of the most widely prescribed antidepressants in the country. The recall potentially affects around 4 million individuals, based on class-action settlement estimates from ClassAction.org.
What N-Nitroso-Duloxetine Is and Why It Matters
N-nitroso-duloxetine forms when the drug's active ingredient reacts with nitrites during manufacturing or storage. Nitrosamines have been linked to cancer in lab studies. The FDA sets a daily intake limit for this specific compound of between 288 and 600 nanograms per day. The recalled lots exceeded that threshold.
Edwin Gump, PhD, of the US Pharmacopeia, described nitrosamines as "fairly nasty cancer-causing actives" but stressed that the risk builds up over a long period of time, according to Oncology News Central. The FDA's position is that one brief exposure does not mean a patient will develop cancer. The agency urges patients not to stop taking the drug without talking to their doctor first.
Stopping the Drug Carries Its Own Serious Risks
Duloxetine is an SNRI — a type of antidepressant that affects both serotonin and norepinephrine in the brain. Stopping it suddenly can trigger what doctors call discontinuation syndrome. Symptoms include dizziness, nausea, and "brain zaps" — brief, electric-shock-like sensations in the head. Experts say this risk is why patients should never quit without guidance.
Kenneth S. Fill, PharmD, warned that Duloxetine carries a high risk of discontinuation syndrome, according to BuzzRx. The FDA echoed this: "patients should talk to their healthcare professional... do not stop taking your medications" without a replacement plan in place. Patients who think they have an affected bottle should call their pharmacist, not simply throw the drug away.
A Nitrosamine Problem Years in the Making
This recall did not happen in a vacuum. The FDA first flagged nitrosamine contamination in 2018 after finding the impurity NDMA in the blood pressure drug Valsartan. Since then, more than 1,400 drug recalls have been tied to nitrosamine impurities, according to industry research. Drugs like Zantac and Metformin were pulled for similar reasons.
Breckenridge has recalled Duloxetine before — in 2015, a foreign tablet was found inside a bottle, per Fierce Pharma. This time, the scale is far larger. The manufacturer of the affected lots is Towa Pharmaceutical Europe, based in Martorelles, Spain. Breckenridge has notified distributors and pharmacies directly, asking them to quarantine all affected stock immediately. A class-action settlement reached in May 2025 offers affected consumers up to $7.50 per prescription.
Sentiment
NeutralPublishers
7
Articles
7
Reach
8
